ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2129 entries already.
Biomanufacturing – either for production of biologics or bio-based everyday products – has traditionally suffered from the unpredictably variable response of production cell lines to external stimuli. Synthetic biology groups now wish to create a network of biofoundries that aim to establish reproducibility standards from process design to product purification and – in the long term – intend to switch from cell-based to cell-free bioproduction.
Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.
BioEcho develops single-spin and 96-well kits for the isolation of DNA. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents resulting in increased sensitivity and reliability of downstream analyses. Therefore, the risk of inhibition or complete failure of PCR applications is eliminated. The process does not require washing steps and is significantly faster than commonly used bind-wash-elute methods.
Lyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019.
Sanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.
Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).
Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.